Indicators
Indicators
Value
Direction
MACD(12,26,9)
-3.153
Neutral
RSI(14)
42.966
Neutral
STOCH(KDJ)(9,3,3)
36.007
Sell
ATR(14)
11.429
High Vlolatility
CCI(14)
-118.597
Sell
Williams %R
80.575
Oversold
TRIX(12,20)
-0.222
Sell
StochRSI(14)
0.000
Sell
Sol Gel Technologies Ltd
SLGL67.790USD
-9.960-12.81%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
121.92MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sol Gel Technologies Ltd
Currency: USD Updated: 2026-03-27Key Insights
Sol Gel Technologies Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 110.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sol Gel Technologies Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sol Gel Technologies Ltd Highlights
StrengthsRisks
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1147.62% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 19.39M.
Undervalued
The company’s latest PE is -36.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 634.85K shares, decreasing 40.95% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
110.000
Target Price
+41.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Sol Gel Technologies Ltd is 6.23, ranking 273 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 696.00K, representing a year-over-year increase of 150.36%, while its net profit experienced a year-over-year increase of 48.91%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
4.00
Operational Efficiency
4.00
Growth Potential
6.10
Shareholder Returns
7.03
Sol Gel Technologies Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Sol Gel Technologies Ltd is 7.34, ranking 129 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -36.01, which is -778.40% below the recent high of 244.30 and -128.96% above the recent low of -82.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 120/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Sol Gel Technologies Ltd is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 50.00 and a low of 50.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
110.000
Target Price
+38.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Sol Gel Technologies Ltd
SLGL
1
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Sol Gel Technologies Ltd is 7.56, ranking 39 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 97.47 and the support level at 61.42, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
76.914
Sell
MA10
76.054
Sell
MA20
81.043
Sell
MA50
75.275
Sell
MA100
58.792
Buy
MA200
40.076
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Sol Gel Technologies Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.79%, representing a quarter-over-quarter increase of 121.96%. The largest institutional shareholder is Invesco, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sol Gel Technologies Ltd is 2.34, ranking 230 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.27
VaR
+8.12%
240-Day Maximum Drawdown
+48.06%
240-Day Volatility
+146.14%
Return
Best Daily Return
60 days
+20.86%
120 days
+23.28%
5 years
+284.62%
Worst Daily Return
60 days
-12.61%
120 days
-12.61%
5 years
-40.62%
Sharpe Ratio
60 days
+2.74
120 days
+2.55
5 years
+0.43
Risk Assessment
Maximum Drawdown
240 days
+48.06%
3 years
+90.71%
5 years
+97.24%
Return-to-Drawdown Ratio
240 days
+36.25
3 years
+0.49
5 years
-0.06
Skewness
240 days
+2.83
3 years
+15.14
5 years
+18.06
Volatility
Realised Volatility
240 days
+146.14%
5 years
+123.31%
Standardised True Range
240 days
+4.90%
5 years
+3.66%
Downside Risk-Adjusted Return
120 days
+456.91%
240 days
+456.91%
Maximum Daily Upside Volatility
60 days
+103.42%
Maximum Daily Downside Volatility
60 days
+96.29%
Liquidity
Average Turnover Rate
60 days
+0.80%
120 days
+3.45%
5 years
--
Turnover Deviation
20 days
-83.00%
60 days
-86.70%
120 days
-42.73%
Peer Comparison
Biotechnology & Medical Research
Sol Gel Technologies Ltd
SLGL
6.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
